| P2093 | author name string | J B Vermorken | |
| | J Dyck | |
| | D Schrijvers | |
| | J Van den Brande | |
| | J Bosmans | |
| | M Rasschaert | |
| | K Merkle | |
| P2860 | cites work | Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma | Q33343780 |
| | Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma | Q33366403 |
| | Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients | Q33373244 |
| | A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors | Q33374826 |
| | Bendamustine | Q34257877 |
| | Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. | Q34734956 |
| | Metabolism and mechanisms of action of bendamustine: rationales for combination therapies | Q34778774 |
| | Phase I studies with bendamustine: an update | Q34778779 |
| | The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function | Q36211375 |
| | Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride | Q40234705 |
| | Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours | Q40616659 |
| | Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours | Q40627330 |
| | In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine | Q40701958 |
| | Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study | Q40831325 |
| | Toxicity of the alkylating agent bendamustin | Q42224728 |
| | Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines | Q44005427 |
| | In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia | Q44161643 |
| | High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas | Q44233737 |
| | Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase acti | Q44569025 |
| | Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). | Q44966920 |
| | Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma | Q46450156 |
| | Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso | Q46886613 |
| | Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine | Q48679005 |
| | Selective uptake of the anticancer drug bendamustine by liver and kidney tissues following its intravenous administration to mice. | Q49088927 |
| | Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. | Q51831972 |
| | Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. | Q53991694 |
| | Aminos�ureantagonisten. III. ?-[Bis-(?-chlor�thyl)-amino-benzimidazolyl-(2)]-propion- bzw. -butters�uren als potentielle Cytostatika | Q57075378 |
| | [Pharmacokinetics of bendamustin (Cytostasan) in B6D2F1-mice] | Q67870047 |
| | Hepatobiliary elimination of bendamustin (Cytostasan) in rats | Q67884893 |
| | [Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine--a phase II study] | Q77662037 |
| | Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and | Q81050174 |
| | Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group | Q81340591 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bendamustine | Q425745 |
| P304 | page(s) | 1692-1698 | |
| P577 | publication date | 2007-05-08 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours | |
| P478 | volume | 96 | |